Amgen and Daiichi Sankyo Co. have entered an exclusive agreement to commercialize nine biosimilars in Japan, including several biosimilars in late-stage development, and biosimilars of adalimumab (Humira), bevacizumab (Avastin) and trastuzumab (Herceptin).   Amgen will be responsible for the development and manufacturing of the biosimilars and Daiichi will file for marketing approval and will be responsible for distribution and commercialization in Japan, while Amgen has limited rights to co-p...